Drug Trial Radar · NCT02262767
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Jan 14, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Nov 2014
Primary completion
Dec 2014
Study completion Dec 2014
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 13, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will test the hypothesis that PF-06649751 with continuous co-administration of trimethobenzamide hydrochloride (TMB) with will be safe and well tolerated. Single doses of PF-06649751 will be tested in this study, starting at a low dose and escalating to a dose projected to be under the current limits for drug concentration.
Conditions
- Healthy
Interventions
PF-06649751Drug
Experimental Pfizer compound.
Trimethobenzamide HydrochlorideDrug
Trimethobenzamide Hydrochloride is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 0 - 4 weeks
- Supine and standing vital sign measurementsTime frame: 0 - 4 weeks
- Electrocardiogram (ECG)Time frame: 0 - 4 weeks
- Number of Participants With Laboratory Test Values of Potential Clinical ImportanceTime frame: 0 - 4 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Belgium Pfizer Clinical Research Unit
Brussels, Belgium
Pfizer Clinical Research Unit
Brussels, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.